Journal
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
Volume 17, Issue 5, Pages 338-347Publisher
BENTHAM SCIENCE PUBL
DOI: 10.2174/1871527317666180612125843
Keywords
Dl-3-n-butylphthalide; ischemic stroke; cerebral microcirculation; neuroprotection; mitochondria; apoptosis; oxidative stress
Categories
Funding
- National Natural Sciences Foundation of China [81373387, 81473200, 81673420]
- CAMS Innovation Fund for Medical Sciences [2017-I2M-2-004]
- Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study [BZ0150]
Ask authors/readers for more resources
Background and Objective: Stroke is a leading cause of morbidity and mortality in both developed and developing countries all over the world. The only drug for ischemic stroke approved by FDA is recombinant tissue plasminogen activator (rtPA). However, only 2-5% stroke patients receive rtPAs treatment due to its strict therapeutic time window. As ischemic stroke is a complex disease involving multiple mechanisms, medications with multi-targets may be more powerful compared with single-target drugs. Dl-3-n-Butylphthalide (NBP) is a synthetic compound based on l-3-n-Butylphthalide that is isolated from seeds of Apium graveolens. The racemic 3-n-butylphthalide (dl-NBP) was approved by Food and Drug Administration of China for the treatment of ischemic stroke in 2002. A number of clinical studies indicated that NBP not only improved the symptoms of ischemic stroke, but also contributed to the long-term recovery. The potential mechanisms of NBP for ischemic stroke treatment may target different pathophysiological processes, including anti-oxidant, anti-inflammation, anti-apoptosis, anti-thrombosis, and protection of mitochondria et al. Conclusion: In this review, we have summarized the research progress of NBP for the treatment of ischemic stroke during the past two decades.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available